 |
 |
Hi All - Yesterday Genzyme/Diacrin, the biomedical company I have been working with, announced results of its Phase 2 research study on pig-cell therapy for Parkinson's Disease. As you know this is a very new and controversial technology. As a participant in Phase 1, I have received considerable benefit from this xenotransplantation. There were 12 of us in that first group. Several (but not all) of us had good results. No one suffered any ill effects. We all had a unilateral transplantation consisting of 12 million cells. Phase 2 recipients each had bilateral implants of a total of 48 million cells. Also this group had 18 members; 10 of which received the cells while the remaining 8 got the "sham" surgery. I am very sorry to report that apparently there were no discernible differences between the "have" and the "have not" members. The question now is --"What was different between Phase 1 and Phase 2?" And, in particular, what was different about me, since I have done particularly well. With this in mind, I have contacted officials at Genzyme/Diacrin and have offered myself for further testing and examination. There is no doubt that this technology offers great hope for our future and that work in this field must continue. You can read the press release at: http://www.genzyme.com/ir/genz/press/20010316.html I will keep you informed as to what develops over the next few months. Jim Finn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn